OS Therapies raises $4.7M but warns it may not survive the year
What's the deal? OS TherapiesDealroom has a profile for this one. Try Dealroom → (NYSE American: OSTX) closed an equity financing on August 10, 2026, raising roughly $4.7 million in net proceeds, with a further $5 million in future borrowings available. The clinical-stage biotech also flagged substantial doubt about its ability to continue as a going concern within one year.
Why now? The raise follows a cash crunch. As of June 30, 2026, OS Therapies held just $205,035 in cash, down from $269,830 at the end of 2025.
Burning fast: The company used $10.1 million in operating activities during the first half of 2026 and posted a net loss of $19.0 million, or $0.46 per share — more than double the $8.4 million loss a year earlier. Research and development spending drove the widening, climbing to $13.4 million from $3.8 million.
Management expects vendor and related costs tied to regulatory preparation with the Food and Drug Administration and other authorities to total about $24.0 million and run through the rest of 2026. It says the current cash balance is insufficient and it is seeking more capital through equity offerings or debt.
Balance sheet strain: Total liabilities reached $20.7 million as of June 30, up from $11.9 million at year-end. The stockholders' deficit widened to $11.9 million from $6.1 million, while accounts payable and accrued expenses jumped to $20.2 million.
Dilution mounts: The company has leaned on serial raises to stay afloat. A $2.0 million bridge financing in March converted into stock and warrants alongside an April registered direct offering that brought in roughly $4.8 million net.
Shares outstanding rose to 45.3 million from 37.1 million over the six months, and outstanding warrants nearly doubled to 13.7 million — pointing to further dilution ahead.
The signal: OS Therapies illustrates the squeeze facing small-cap biotechs that must fund costly regulatory work while burning through cash faster than they can raise it. Each round buys time but deepens dilution, and the going-concern flag underscores how thin the runway has become.
Read more: MiniChart
Image credit: Generated with Gemini
